Syngene International Limited
NSE: SYNGENEMarket Closed • NSE
Day range
52 week range
Syngene International Limited closed at INR347.40 (+0.4%) on volume 0.63x its 20-day average, trading 48.83% below its 52-week high.
2026-Q2
Q2 FY2026 Financial Results
PAT moved -106.1% QoQ
2026-06-25
DIVIDEND Announced
Dividend - Rs 1.25 Per Share
2025-06-27
DIVIDEND Announced
Dividend - Rs 1.25 Per Share
Revenue and PAT bars use independent scales to make their year-on-year direction readable.
Complete reported financial history · Values use the company's reporting currency
Hover over the chart for exact reported values. Percentage lines use the right-hand axis.
A 0–100 quantitative summary of reported fundamentals. Use the underlying financials and risks for context; the score is not a buy or sell recommendation.
Strengths
Low Debt Profile: Debt-to-Equity is comfortable at 0.09x
High Cash Flow Conversion: CFO/PAT averaged 2.65x over last 3 years
Risks
Stretched Valuation: Trading at a high P/E multiple of 63.3x
Bull case
Market Leadership: Established operational scale in Diagnostics & Research.
Bear case
Macro Headwinds: Fluctuations in interest rates and sector-specific policy shifts could compress multiples.
Flip condition
Sustained quarterly EBITDA margin expansion above 20% would trigger an upgrade.
Ownership distribution
Category trends
Hover over a period for exact holdings
Complete dividend, bonus, split, rights and other action history
| Record date | Corporate action | Information | Announcement date | Ex-date |
|---|---|---|---|---|
| 26 Jun 2026 | Dividend | ₹1.25 / share | — | 25 Jun 2026 |
| 27 Jun 2025 | Dividend | ₹1.25 / share | — | 27 Jun 2025 |
| 28 Jun 2024 | Dividend | ₹1.25 / share | — | 28 Jun 2024 |
| 30 Jun 2023 | Dividend | ₹0.50 / share | — | 30 Jun 2023 |
| 01 Jul 2022 | Dividend | ₹0.50 / share | — | 30 Jun 2022 |
| 14 Jul 2021 | Annual General Meeting | Annual General Meeting | — | 13 Jul 2021 |
| 17 Jul 2019 | Dividend | ₹0.50 / share | — | 16 Jul 2019 |
| 12 Jun 2019 | Bonus issue | 1:1 bonus ratio | — | 11 Jun 2019 |
| 18 Jul 2018 | Dividend | ₹1.00 / share | — | 17 Jul 2018 |
| 21 Jul 2017 | Dividend | ₹1.00 / share | — | 20 Jul 2017 |
| 19 Mar 2016 | Dividend | ₹1.00 / share | — | 17 Mar 2016 |
Traded volume and delivery percentage across the latest 20 sessions
Compare valuation, latest quarterly performance and year-on-year growth
| Company name | Market cap ₹ Cr | P/E ratio | Dividend yield % | Quarterly sales ₹ Cr | Profit after tax ₹ Cr | Sales growth % | Profit growth % |
|---|---|---|---|---|---|---|---|
 Sun Pharmaceutical Industries LimitedSUNPHARMA Open analysis | ₹4.22L | 34.92 | 0.91% | ₹15,300.00 | ₹2,901.00 | +10.46% | +26.52% |
 Divi's Laboratories LimitedDIVISLAB Open analysis | ₹2.48L | 84.75 | 0.32% | ₹3,080.00 | ₹902.00 | +27.80% | +65.50% |
 Torrent Pharmaceuticals LimitedTORNTPHARM Open analysis | ₹1.77L | 74.39 | 0.82% | ₹4,128.00 | ₹389.00 | +41.90% | -21.89% |
 LENSKART SOLUTIONS LTDLENSKART Open analysis | ₹1.17L | 183.15 | 0.00% | ₹2,714.00 | ₹228.00 | +43.29% | +273.77% |
 Apollo Hospitals Enterprise LimitedAPOLLOHOSP Open analysis | ₹1.15L | 55.26 | 0.26% | ₹7,044.00 | ₹610.00 | +20.58% | +38.32% |
 Zydus Lifesciences LimitedZYDUSLIFE Open analysis | ₹1.11L | 24.91 | 0.09% | ₹8,017.00 | ₹990.00 | +21.95% | -34.91% |
 Laurus Labs LimitedLAURUSLABS Open analysis | ₹1.10L | 100.67 | 0.12% | ₹2,026.31 | ₹367.60 | +29.10% | +125.49% |
 Cipla LimitedCIPLA Open analysis | ₹1.05L | 31.20 | 0.99% | ₹7,119.00 | ₹786.00 | +2.33% | -39.16% |
Syngene (established in 1993) as a Biocon subsidiary is India's first Contract Research Organization (CRO) which expanded later to be an integrated service provider offering end-to-end drug discovery, development, and manufacturing services on a single platform (CRAMS). Total research & manufacturing infrastructure for the company is spread across 1.9 million square feet across locations. [1]
IndiaHealthcare
Is Syngene International Limited Shariah compliant?
Syngene International Limited is currently screened as Shariah Compliant under AAOIFI Shariah Standard No. 21. Business activities align with Shariah permissible sectors. Debt to Market Cap (3.28%) complies with AAOIFI threshold (≤ 33%).
What is Syngene International Limited's current valuation relative to peers?
Syngene International Limited trades at a P/E of 63.3x compared to the sector median of 37.6x, and a Price-to-Book of 2.9x.
Is the company financially healthy?
The company has a Debt-to-Equity ratio of 0.09x. Interest coverage is 10.8x.
What are the historical revenue and profit growth rates?
Over the past 5 years, revenue compounded at 2.1% while net profit growth averaged -9.1%.
Market data is informational and may be delayed. Shariah screening follows the displayed methodology. This is not investment advice.
Market data may be delayed. Quote date: 2026-10-09. Financial figures relate to their stated reporting periods. This information is for research and is not a recommendation to buy or sell.